Antidiabetic Drug Mimics Exercise Benefits in Cancer Patients

A new study has found that a widely used diabetes medication may produce metabolic effects similar to those of physical exercise in cancer patients, offering a potential avenue for improving treatment outcomes in oncology care.

The research, published in the journal Cell Metabolism, investigated the impact of metformin — a first-line drug for type 2 diabetes — on metabolic pathways in individuals undergoing cancer treatment. Scientists observed that metformin activated cellular processes typically triggered by physical activity, including increased glucose uptake in muscles and enhanced mitochondrial function, without requiring patients to engage in exercise.